NEWS
Atara Biotherapeutics Announces Second Quarter 2024 Financial Results, Operational Progress and Leadership Update
Atara Biotherapeutics (Nasdaq: ATRA) reported Q2 2024 financial results and operational progress. Key highlights include:
1. Tab-cel® U.S. BLA accepted under Priority Review with PDUFA date of January 15, 2025.
2. ATA3219 studies in Lupus Nephritis and Severe Systemic Lupus Erythematosus to start Q4 2024; initial data expected mid-2025.
3. ATA3219 Non-Hodgkin's Lymphoma study enrolling; initial data expected Q1 2025.
4. Leadership changes: Pascal Touchon to become Chairman, Cokey Nguyen to be appointed President and CEO effective September 9, 2024.
5. Q2 2024 revenues: $28.6 million; net loss: $19.0 million ($3.10 per share).
6. Cash runway extended into 2027, enabling key pipeline readouts.
1. Tab-cel® U.S. BLA accepted under Priority Review with PDUFA date of January 15, 2025.
2. ATA3219 studies in Lupus Nephritis and Severe Systemic Lupus Erythematosus to start Q4 2024; initial data expected mid-2025.
3. ATA3219 Non-Hodgkin's Lymphoma study enrolling; initial data expected Q1 2025.
4. Leadership changes: Pascal Touchon to become Chairman, Cokey Nguyen to be appointed President and CEO effective September 9, 2024.
5. Q2 2024 revenues: $28.6 million; net loss: $19.0 million ($3.10 per share).
6. Cash runway extended into 2027, enabling key pipeline readouts.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Trytosaveabit : I can’t believe with the monster revenue increase this isn’t moving! Over 2000% increase
Jaguar8 OP Trytosaveabit : Maybe let’s wait tomorrow. Maybe they are too happy with their GNLN earnings![undefined [undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36)
![undefined [undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36)
Trytosaveabit Jaguar8 OP : Hehehe! Yeah you’re right.
Joo Mey : hye dude..what do you think about ffie?
Jaguar8 OP Joo Mey : I try to avoid it. Super high ritual for dilution. Negative cash flow